Eagle Bay Advisors’s AbCellera Biologics ABCL Stock Holding History

Eagle Bay Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-710	Closed	-$2.08K	–	116
2024 Q4	$2.08K	Hold	710	–	–	﹤0.01%	871
2024 Q3	$1.85K	Hold	710	–	–	﹤0.01%	1241
2024 Q2	$2.1K	Hold	710	–	–	﹤0.01%	880
2024 Q1	$3.22K	Hold	710	–	–	﹤0.01%	819
2023 Q4	$4.05K	Hold	710	–	–	﹤0.01%	668
2023 Q3	$3.27K	Hold	710	–	–	﹤0.01%	720
2023 Q2	$4.59K	Buy	710 +355	+100%	+$2.42K	﹤0.01%	679
2023 Q1	$2.68K	Hold	355	–	–	﹤0.01%	730
2022 Q4	$3.6K	Sell	355 -900	-72%	-$10.4K	﹤0.01%	707
2022 Q3	$12K	Hold	1,255	–	–	0.01%	571
2022 Q2	$13.4K	Buy	+1,255	New	+$10.6K	0.01%	606
2022 Q1	–	Sell	-4,463	Closed	-$85K	–	294
2021 Q4	$85K	Buy	4,463 +1,363	+44%	+$20.7K	0.05%	222
2021 Q3	$62K	Buy	3,100 +1,300	+72%	+$23K	0.03%	344
2021 Q2	$40K	Buy	+1,800	New	+$49.6K	0.03%	391

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eagle Bay Advisors's ABCL Position: Q1 2025 in Review

Eagle Bay Advisors sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 710 shares — an estimated $2.08K sold.

Eagle Bay Advisors first reported a position in ABCL in Q2 2021 and held it in 14 quarters. The position peaked at $85K in Q4 2021. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

Eagle Bay Advisors reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 710 AbCellera Biologics shares in Q1 2025, an estimated $2.08K.
Eagle Bay Advisors first reported a position in AbCellera Biologics in Q2 2021 and held it in 14 quarters.
Eagle Bay Advisors's AbCellera Biologics position peaked at $85K in Q4 2021.
129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.